Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug approvals and failures: implications for alliances

Nature Reviews Drug Discovery volume 7, pages 197–198 (2008)Cite this article

The low number of drugs originating from large pharmaceutical companies despite growth in R&D expenditure and the increasing importance of biotech companies as a source of innovative potential therapies have been widely noted in recent years. With the aim of investigating these trends, we analysed the origins of drugs approved by the FDA and those failing in Phase III trials during the period January 2006 to December 2007. This analysis is based on our assessment of data reported in BioCentury Stock Wrap-Up articles, which summarize approvals and setbacks in the industry for each quarter1,2,3,4,5,6,7,8. Biotech companies are those included in the American Stock Exchange Biotech Index and/or the Nasdaq Biotechnology Index.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. No Author listed. 1Q Stock Wrap-Up. BioCentury 14, No.15, 9–11 (2006).

  2. No Author listed. 2Q Stock Wrap-Up. BioCentury 14, No. 29, 10–13 (2006).

  3. No Author listed. 3Q Stock Wrap Up. BioCentury 14, No. 43, 10–13 (2006).

  4. Edelson, S. 4Q Stock Wrap-Up. BioCentury 15, No. 1, 8–12 (2007).

    Google Scholar 

  5. No Author listed. 1Q Stock Wrap-Up. BioCentury 15, No. 15, 9–12 (2007).

  6. Lawrence S. 2Q Stock Wrap-Up. BioCentury 15, No. 29, 10–13 (2007).

  7. Lawrence, S. 3Q Stock-Wrap-Up. BioCentury 15 No. 43, 9–12 (2007).

    Google Scholar 

  8. Lawrence, S. 4Q Stock Wrap-Up. BioCentury 16 No. 2, 20–25 (2008).

    Google Scholar 

  9. Sabo, S. The current status of targeted therapies for breast cancer: an interview with Kathy Miller, MD. Medscape web site [online], (2003).

    Google Scholar 

  10. Keymeulen, B. et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598–2608 (2005).

    Article  CAS  Google Scholar 

  11. Drews, J. & Ryser, S, Innovation deficit in the pharmaceutical industry. Drug Inf. J. 30, 97–107 (1996).

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Elizabeth A. Czerepak and Stefan Ryser, Ph.D. are both Founding Partners of Bear Stearns Health Innoventures, LLC (BSHI), of which Bear Stearns Asset Management is a General Partner. The authors are employees of Bear Stearns Asset Management, a subsidiary of Bear Stearns & Co., 237 Park Avenue, 7th Floor, New York, New York 10017, USA. eczerepak@bear.com; sryser@bear.com

Authors
  1. Elizabeth A. Czerepak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Ryser
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Supplementary information S1 (table)

US FDA drug approvals from January 2006–December 2007 (PDF 343 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Czerepak, E., Ryser, S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov 7, 197–198 (2008). https://doi.org/10.1038/nrd2531

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2531

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing